×
More Charts Below
Hypermarcas Return On Tangible Equity 2010-2024 | HYPMY
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Current Ratio
Quick Ratio
Debt/Equity Ratio
ROE
ROA
ROI
Return Tangible Eq
Recent Trends
Hypermarcas return on tangible equity from 2010 to 2024. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$95B
Zoetis (ZTS)
$66.3B
Takeda Pharmaceutical (TAK)
$46.8B
Daiichi Sankyo, - (DSNKY)
$41.7B
Summit Therapeutics (SMMT)
$18.2B
Sandoz Group AG (SDZNY)
$17.7B
Merck (MKKGY)
$17.2B
Astellas Pharma (ALPMY)
$16.9B
Shionogi (SGIOY)
$14.1B
United Therapeutics (UTHR)
$12.8B
Neurocrine Biosciences (NBIX)
$10B
IPSEN (IPSEY)
$8.6B
Orion OYJ (ORINY)
$8B
Madrigal Pharmaceuticals (MDGL)
$6.7B
Stevanato Group S.p.A (STVN)
$6.6B
Corcept Therapeutics (CORT)
$6.6B
Hikma Pharmaceuticals Plc (HKMPF)
$5.8B
Ono Pharmaceutical (OPHLF)
$5.5B
Grifols, S.A (GRFS)
$4.9B
Ionis Pharmaceuticals (IONS)
$4.5B
Soleno Therapeutics (SLNO)
$3.2B
Crinetics Pharmaceuticals (CRNX)
$2.8B
Catalyst Pharmaceuticals (CPRX)
$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.3B
Recursion Pharmaceuticals (RXRX)
$2.2B
NewAmsterdam Pharma (NAMS)
$1.8B
Centessa Pharmaceuticals (CNTA)
$1.6B
BioCryst Pharmaceuticals (BCRX)
$1.5B
Guardian Pharmacy Services (GRDN)
$1.5B
ARS Pharmaceuticals (SPRY)
$1.5B